Lung cancers
280 results
1 - 100
Screening for lung cancer- Exercise training for advanced lung cancer
- Drugs for preventing lung cancer in healthy people
- Interventions for smoking cessation in people diagnosed with lung cancer
- Chemotherapy for non‐small cell lung cancer
- Elemene for the treatment of lung cancer: Cochrane systematic review
- Surgery for limited‐stage small‐cell lung cancer
- Postoperative radiotherapy for non‐small cell lung cancer
- Chemotherapy for brain metastases from small cell lung cancer
- Second‐line chemotherapy for non‐small cell lung cancer
- Palliative endobronchial brachytherapy for non‐small cell lung cancer
- Concurrent chemoradiotherapy in non‐small cell lung cancer
- Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
- Surgery for local and locally advanced non‐small cell lung cancer
- Therapeutic vaccines for advanced non‐small cell lung cancer
- Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
- Non‐invasive interventions for improving well‐being and quality of life in patients with lung cancer
- Perioperative immunotherapy strategies for resectable non‐small cell lung cancer
- Preoperative exercise training for people with non‐small cell lung cancer
- Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer
- Consolidative thoracic radiotherapy for extensive disease small cell lung cancer
- Surgery versus radiosurgery for patients with a solitary brain metastasis from non‐small cell lung cancer
- Prophylactic cranial irradiation for extensive‐stage small cell lung cancer
- Early versus late chest radiotherapy in patients with limited‐stage small cell lung cancer
- Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer
- Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
- Chemotherapy for advanced non‐small cell lung cancer in the elderly population
- Gefitinib for advanced non-small cell lung cancer: Cochrane systematic review
- Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
- Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
- Surgical sealant for preventing air leaks after pulmonary resections in patients with lung cancer: Cochrane systematic review
- Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission: Cochrane systematic review
- Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non‐small cell lung cancer
- Radical radiotherapy for stage I/II non‐small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable)
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer: Cochrane systematic review
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer: Cochrane systematic review
- Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer: Cochrane systematic review
- Chemotherapy versus best supportive care for extensive small cell lung cancer: Cochrane systematic review
- Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease: Cochrane systematic review
- PET‐CT for assessing mediastinal lymph node involvement in patients with suspected resectable non‐small cell lung cancer
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
- First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation
- Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer
- Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non‐small cell lung cancer: a systematic review and network meta‐analysis
- Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer
- Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
- Anti‐TIGIT inhibitors plus PD‐1 or PD‐L1 inhibitors versus PD‐1 or PD‐L1 inhibitors for first‐line treatment of advanced non‐small cell lung cancer